- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00142935
Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1
Opiate Replacement Therapy at Release From Incarceration
Study Overview
Status
Conditions
Detailed Description
A substantial proportion of individuals addicted to heroin are incarcerated while addicted and a majority of individuals released from a correctional setting have a history of heroin addiction. The period immediately after release from incarceration is a particularly high-risk time for HIV transmission and other problems, including drug relapse and overdose. Methadone treatment is the most widely used opiate replacement therapy in the United States and has been shown to decrease HIV risk, as well as drug use, addiction relapse, and criminal activity. The purpose of this study was to evaluate the effectiveness of initiating opiate replacement therapy prior to release from incarceration on reducing HIV risk behaviors and drug relapse. In addition, this study evaluated the effectiveness of short-term payment versus non-payment of community opiate replacement therapy immediately following release from incarceration.
Participants in this were randomly assigned to 1 of 3 treatment groups. Participants enrolled in Group 1 initiated methadone opiate replacement therapy about 1 month prior to release from incarceration. They proceeded with a methadone program of their choice upon release and received short-term payment to cover treatment costs. Participants enrolled in Group 2 were referred to a methadone program of their choice and received short-term payment to cover treatment costs. Participants enrolled in Group 3 were referred to a program of choice upon release from incarceration without receiving financial assistance. All participants had the opportunity to partake in existing support programs available at the Rhode Island Department of Corrections while incarcerated and in the community upon release. Follow-up assessments occurred at Months 1.5, 6, and 12. These included interviews and urine specimens for toxicology analysis to verify self-reports.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02906
- The Miriam Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Currently incarcerated at the Rhode Island Department of Corrections with a scheduled release date at least 28 days after enrollment
- Incarceration length not to have exceeded two years at the time of enrollment
- Heroin dependent with self-reported heroin injection in the month prior to incarceration OR enrollment in a methadone treatment program prior to incarceration for heroin addiction with a history of injection drug use
- Desire to enter methadone treatment upon release and plans to secure funding for methadone treatment after study completion
- History of prior tolerance to methadone
- History of at least one drug-related incarceration
- Speaks English or Spanish
- Plans to remain in Rhode Island for the duration of the study (24 months)
- Ability to provide at least two names of individuals who can verify participant information
Exclusion Criteria:
- Currently receiving methadone at the Rhode Island Department of Corrections
- Currently undergoing a non-narcotic detoxification from illicit opiates at the Rhode Island Department of Corrections
- Plans to leave Rhode Island within the two years following enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pre-Release Initiation MMT
Participants assigned to this arm will undergo extensive assessment (physical, medical history, drug use and treatment history) prior to initiating treatment.
MMT will begin 1-30 days prior to release from incarceration.
MMT first dose will begin at 5 mg with 2 mg increase per day until release or therapeutic dose of 60-120 mg is achieved.
Daily observation by dosing nurses and twice weekly symptom review by Research Assistant will occur.
Additionally, participants assigned to Arm 1 will have all logistical arrangements made for entry into a community methadone clinic program within 24 hours of release from incarceration.
The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
|
Participants assigned to arm 1 will undergo extensive assessment (physical, medical history, drug use and treatment history) prior to initiating treatment.
MMT will begin 1-30 days prior to release from incarceration.
MMT first dose will begin at 5 mg with 2 mg increase per day until release or therapeutic dose of 60-120 mg is achieved.
Daily observation by dosing nurses and twice weekly symptom review by Research Assistant will occur.
Additionally, participants assigned to Arm 1 will have all logistical arrangements made for entry into a community methadone clinic program within 24 hours of release from incarceration.
The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
|
Experimental: Post Release Initiation of MMT
Participants assigned to this arm will have all logistical arrangements made for entry into a community methadone clinic program within 24-48 hours of release from incarceration.
The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
|
Participants assigned to Arm 2 will have all logistical arrangements made for entry into a community methadone clinic program within 24-48 hours of release from incarceration.
The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
|
Active Comparator: Standard of Care Plus
Participants assigned to this arem will not begin treatment prior to release from incarceration or have treatment paid for by the study.
However, study staff will work with participants to identify ways to pay for treatment, including assisting with medicaid applications, etc. Further, the study will make the logistical arrangements for entering treatment if participant has a means to finance MMT.
|
Participants assigned to Arm 3 will not begin treatment prior to release from incarceration or have treatment paid for by the study.
However, study staff will work with participants to identify ways to pay for treatment, including assisting with medicaid applications, etc. Further, the study will make the logistical arrangements for entering treatment if participant has a means to finance MMT.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Engagement
Time Frame: within 30 days post release of incarceration
|
Participants are considered to have successfully initiated community methadone maintenance treatment only if they make their first clinic appointment within 30 days after being released from incarceration.
This outcome is measured by frequency - yes, participant attended initial clinic appointment within 30 days post release or no, participant did not attend clinic appointment within 30 days post release.
Data source was methadone clinic chart review.
|
within 30 days post release of incarceration
|
Time to MMT Initiation Post Release Based on Clinic Chart Review
Time Frame: within 30 days post release from incarceration
|
Participants are considered to have successfully initiated community methadone maintenance treatment only if they make their first clinic appointment within 30 days after being released from incarceration.
This outcome measures number of days from release to the first day of clinic attendance, only for those participants who successfully entered methadone treatment post release.
Data source was methadone clinic chart review.
|
within 30 days post release from incarceration
|
HIV Risk Behaviors - Self Report
Time Frame: 6 month follow-up interviews
|
Participants who self-reported injecting illicit drugs in the past 30 days, based on responses to face-to-face administration of the 6 month interview.
|
6 month follow-up interviews
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Drug Use
Time Frame: 6 month follow-up interviews
|
Participants who self-reported heroin use in the past 30 days, based on responses to face-to-face administration of the 6 month interview.
|
6 month follow-up interviews
|
Fatal Overdose
Time Frame: Within six months from release of incarceration
|
Number of participants who died as the result of drug poisoning within six months of release of incarceration.
This outcome was based on review of death records.
|
Within six months from release of incarceration
|
Non-fatal Overdose
Time Frame: 6 month follow-up interviews
|
Participants who self-reported experiencing an overdose within the past six months, based on responses to face-to-face administration of the 6 month interview.
|
6 month follow-up interviews
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Josiah D Rich, M.P.H., M.D., The Miriam Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NIDA-18641-1
- DPMC (Other Identifier: NIDA)
- R01-DA018641-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Prevention
-
Prof Mags BeksinskaCompletedHIV Prevention | Pregnancy PreventionSouth Africa
-
Yale UniversityCompletedHIV Prevention | STI PreventionUnited States
-
Centers for Disease Control and PreventionUniversity of Minnesota; The Fenway Institute; AIDS Action Committee of Massachusetts and other collaboratorsCompletedHIV Prevention | STD PreventionUnited States
-
International Partnership for Microbicides, Inc.CompletedHIV PreventionSouth Africa, Uganda
-
Microbicide Trials NetworkNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsCompleted
-
Fenway Community HealthCompleted
-
University of California, Los AngelesUniversity of California, San Diego; California HIV/AIDS Research Program; Los... and other collaboratorsCompletedHIV PreventionUnited States
-
Microbicide Trials NetworkNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsCompletedHIV PreventionUganda, South Africa, Zimbabwe
-
Massachusetts General HospitalMbarara University of Science and TechnologyCompleted
-
Orion Biotechnology Polska Sp. z o.o.Scope International AGCompleted
Clinical Trials on Pre-release Initiation of MMT
-
Arizona State UniversityUniversity of Washington; National Institute on Deafness and Other Communication...RecruitingHealthy Subjects | Stuttering, DevelopmentalUnited States
-
Yale UniversityNational Institute on Drug Abuse (NIDA); Centers for Disease Control and Prevention and other collaboratorsCompleted
-
University of FloridaNational Institute of Nursing Research (NINR)CompletedBreast Milk ExpressionUnited States
-
University of California, Los AngelesTerminatedHealth Care Utilization | Youth IncarcerationUnited States
-
Brigham and Women's HospitalHarvard Medical School (HMS and HSDM); Weill Medical College of Cornell University and other collaboratorsUnknown
-
The Hospital for Sick ChildrenRecruitingSleep-Disordered BreathingCanada
-
Temple UniversityCompletedDiabetic RetinopathyUnited States
-
IP Santé DomicileUnknown
-
University of MinnesotaMedtronic DiabetesCompletedDiabetes Mellitus | Chronic PancreatitisUnited States
-
Medtronic DiabetesCompletedType 1 DiabetesUnited States